AMA announces CPT codes for AstraZeneca’s COVID-19 vaccine
The American Medical Association (AMA) recently updated the CPT code set to include immunization and administration codes for a COVID-19 vaccine under development by AstraZeneca and the University of Oxford.
The new CPT codes will go into effect if and when the vaccine receives approval or emergency use authorization from the Food and Drug Administration, according to the AMA.
The new vaccine-specific product code is:
- 91302, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative-free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use
The following new HCPCS Level II codes will be used to report the administration of two distinct, required doses of the vaccine:
- 0021A, immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; first dose
- 0022A, …; second dose
Notably, the AMA last month announced CPT codes specific to the COVID-19 vaccines developed by Pfizer and Moderna.
Additional information on vaccine-specific CPT codes can be accessed on the AMA’s website.